# Probiotic on Type 2 Diabetes and Chronic Obstruction Pulmonary Disease

> **NCT05492448** · NA · TERMINATED · sponsor: **Glac Biotech Co., Ltd** · enrollment: 30 (actual)

## Conditions studied

- Type 2 Diabetes
- Chronic Obstructive Pulmonary Disease

## Interventions

- **DIETARY_SUPPLEMENT:** Placebo
- **DIETARY_SUPPLEMENT:** L. salivarius AP-32 and L. reuteri GL-104
- **DIETARY_SUPPLEMENT:** L. reuteri GL-104

## Key facts

- **NCT ID:** NCT05492448
- **Lead sponsor:** Glac Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-09-19
- **Primary completion:** 2025-08-15
- **Final completion:** 2025-12-31
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Insufficient funds
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05492448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05492448, "Probiotic on Type 2 Diabetes and Chronic Obstruction Pulmonary Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05492448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*